1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Glabellar Rhytides Global Clinical Trials Review, H1, 2016

Glabellar Rhytides Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Glabellar Rhytides Global Clinical Trials Review, H1, 2016" provides an overview of Glabellar Rhytides clinical trials scenario. This report provides top line data relating to the clinical trials on Glabellar Rhytides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Glabellar Rhytides Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Glabellar Rhytides to Dermatology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Glabellar Rhytides to Dermatology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Glabellar Rhytides Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Glabellar Rhytides 30
Apr 07, 2016: ALPHAEON Announces Results from Two Phase III Trials of DWP-450 Botulinum Toxin Type A 30
Mar 05, 2016: Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology 30
Clinical Trial Profile Snapshots 32
Appendix 83
Abbreviations 83
Definitions 83
Research Methodology 84
Secondary Research 84
About GlobalData 85
Contact Us 85
Disclaimer 85
Source 86

List of Tables
Glabellar Rhytides Therapeutics, Global, Clinical Trials by Region, 2016* 6
Glabellar Rhytides Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Glabellar Rhytides Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Glabellar Rhytides Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9
Glabellar Rhytides Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Glabellar Rhytides Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Glabellar Rhytides Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Glabellar Rhytides Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Glabellar Rhytides to Dermatology Clinical Trials, G7 Countries (%), 2016* 14
Glabellar Rhytides Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Glabellar Rhytides Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Glabellar Rhytides to Dermatology Clinical Trials, E7 Countries (%), 2016* 17
Glabellar Rhytides Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Glabellar Rhytides Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Glabellar Rhytides Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Glabellar Rhytides Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Glabellar Rhytides Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Glabellar Rhytides Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Glabellar Rhytides Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Glabellar Rhytides Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Glabellar Rhytides Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Glabellar Rhytides Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Glabellar Rhytides Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Glabellar Rhytides Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Glabellar Rhytides Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Glabellar Rhytides Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Glabellar Rhytides Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9
Glabellar Rhytides Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Glabellar Rhytides Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Glabellar Rhytides Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Glabellar Rhytides to Dermatology Clinical Trials, G7 Countries (%), 2016* 14
Glabellar Rhytides Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Glabellar Rhytides Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Glabellar Rhytides to Dermatology Clinical Trials, E7 Countries (%), 2016* 17
Glabellar Rhytides Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Glabellar Rhytides Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Glabellar Rhytides Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Glabellar Rhytides Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Glabellar Rhytides Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Glabellar Rhytides Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Glabellar Rhytides Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Glabellar Rhytides Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Glabellar Rhytides Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Glabellar Rhytides Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Glabellar Rhytides Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 84

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Dermatology

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.